Patents by Inventor Shinsei Fujimura

Shinsei Fujimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210222177
    Abstract: An object of the present disclosure is to provide a novel therapeutic agent for a cartilage-related disease, having cartilage regenerating action. Since a substance having SIK2 inhibitory action has chondrocyte differentiation promoting action, a therapeutic agent containing a substance having SIK2 inhibitory action is useful as a therapeutic agent having cartilage regenerating action for cartilage-related diseases such as cartilage damage or osteoarthritis.
    Type: Application
    Filed: July 31, 2019
    Publication date: July 22, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Yuki TSUMORI, Yasutomo NAKANISHI, Shinsei FUJIMURA
  • Patent number: 9085523
    Abstract: The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: July 21, 2015
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuo Obitsu, Kousuke Tani, Hikaru Sugihara, Akio Nishiura, Shinsei Fujimura
  • Publication number: 20140171388
    Abstract: The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders.
    Type: Application
    Filed: August 3, 2012
    Publication date: June 19, 2014
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuo Obitsi, Kousuke Tani, Hikaru Sugihara, Akio Nishiura, Shinsei Fujimura
  • Publication number: 20080033033
    Abstract: The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc.
    Type: Application
    Filed: May 16, 2007
    Publication date: February 7, 2008
    Inventors: Tohru Kambe, Toru Maruyama, Kaoru Kobayashi, Kousuke Tani, Yoshihiko Nakai, Toshihiko Nagase, Takayuki Maruyama, Kiyoto Sakata, Hideyuki Yoshida, Shinsei Fujimura, Akio Nishiura, Nobutaka Abe
  • Patent number: 7256211
    Abstract: The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and/or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: August 14, 2007
    Assignee: ONO Pharmaceutical Co., Ltd.
    Inventors: Tohru Kambe, Toru Maruyama, Kaoru Kobayashi, Kousuke Tani, Yoshihiko Nakai, Toshihiko Nagase, Takayuki Maruyama, Kiyoto Sakata, Hideyuki Yoshida, Shinsei Fujimura, Akio Nishiura, Nobutaka Abe